This is a welcome text with instructions

Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date
on information
about hepatitis and to answer some of our web site and training audience questions.
People are encouraged to submit questions
and post comments.

Be sure to check out our other blog: Hepatitis & Tattoos

Alan Franciscus
Editor-inChief
HCV Advocate
HBV Advocate


Thursday, November 10, 2011

Incivek, Victrelis Working Well in HIV/HCV Coinfection Studies

Roughly 70 percent of people living with HIV and hepatitis C virus (HCV) coinfection have undetectable HCV viral loads after 24 weeks of treatment with either Incivek (telaprevir) or Victrelis (boceprevir) plus pegylated interferon and ribavirin, according to interim results from two studies reported at two recent medical conferences.

Though final proof of the drugs’ effectiveness won’t be known until hepatitis C treatment is stopped and all coinfected people in the trials are followed for an additional six months, rates of undetectable viral loads among those using triple-drug treatment are currently 16 percent to 36 percent above those using only pegylated interferon and ribavirin.

Read more....

0 comments:

Post a Comment